Background: mineralocorticoid receptor antagonists (MRAs) improve outcomes in several populations of patients with heart failure (HF), but there has been no systematic review of MRAs in older patients. Objectives: systematic review and meta-analysis of the efficacy and safety of MRA treatment in elderly HF patients. Data sources: trials were identified through a literature search until 24 January 2015. Study selection: randomised controlled trials (RCTs) of MRAs in patients with HF and/or left ventricular systolic dysfunction aged ≥65 years, with subgroup analysis of patients ≥65 years or with mean participant age ≥70 years. Data extraction and synthesis: efficacy outcomes were mortality, hospitalisation for cardiovascular causes, symptom status or functional capacity. Safety outcomes were hyperkalaemia and renal dysfunction. Data were analysed using relative risk ratios with 95% confidence intervals. Relative risk ratios were pooled where more than three estimates were available. Results: seven RCTs were included (total n = 8,638). Three RCTs in HF with reduced ejection fraction (HEFREF) reported overall benefit from MRA therapy with no significant treatment interaction for age; the effects of MRAs on mortality in patients ≥75 years displayed marked inter-study heterogeneity. In four RCTs of HF with preserved ejection fraction (HEFPEF), MRA treatment had no significant effect on any efficacy outcome. Conclusions: MRAs improve clinical outcomes in selected cohorts of older patients with HEFREF but not HEFPEF. In patients ≥75 years with HEFREF, the effect of MRA treatment on overall mortality is uncertain. Further study is required in subgroups of elderly patients with both HEFREF and HEFPEF.
Introduction
Heart failure (HF) is an increasing global public health problem that results in premature mortality, recurrent hospitalisation and debilitating symptoms and imposes a huge economic burden on healthcare resources [1] . Increasingly, HF represents a disease of older people with a population prevalence of 9-10% in individuals aged 75-84 years, and 17-18% in those aged 85 and older, compared with <1% in patients <65 years [2] . Within the UK, the median age of patients hospitalised with HF is now 80 years [3] .
Despite major advances in evidence-based treatments for HF with reduced ejection fraction (HEFREF), older patients remain under-represented in clinical trials and have substantially worse outcomes than younger patients [4] [5] [6] . Age-related physiological changes, comorbidity, frailty, polypharmacy and altered drug pharmacokinetics may all attenuate the potential benefit from drug therapy in elderly HF patients and increase the risk of side effects and complications [7] . Moreover, the prevalence of HF with preserved ejection fraction (HEFPEF), a condition with a lack of proven therapies, is proportionately far greater in the elderly HF population [6, 8, 9] . It is therefore essential to know whether recommended treatments are efficacious and safe for older people.
Mineralocorticoid receptor antagonists (MRAs) have been shown to reduce mortality and hospitalisation in several cohorts of patients with HEFREF [10] [11] [12] and have recently been tested in patients with HEFPEF [13, 14] . To date, there has been no dedicated systematic review of the effects of MRA treatment in older patients with HF. We therefore sought to clarify the efficacy and safety of MRAs in older HF patients with both reduced and preserved ejection fraction.
Methods Search strategy and selection criteria
We performed a systematic review and report it using the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines [15] . Retrieved results were filtered to include randomised controlled trials (RCTs) that fulfilled one or more of the following conditions: (i) enrolled only patients aged ≥65 years, (ii) included subgroup analysis of patients aged ≥65 years or (iii) had a mean participant age of ≥70 years. The drugs of interest were spironolactone, epleronone and canrenone. Trials were required to include patients with HF of any aetiology and/ or left ventricular systolic dysfunction (LVSD, LV ejection fraction <40%) and to report at least one relevant clinical efficacy or safety outcome. The primary efficacy outcome was all-cause mortality. Secondary efficacy outcomes were cardiovascular mortality, hospitalisation for cardiovascular causes, symptom status (validated quality of life assessment tools, New York Heart Association (NYHA) class) or functional capacity (6-minute walk test, VO 2 max). Safety outcomes were hyperkalaemia and renal dysfunction, defined as per the primary trial publication.
Data source and study search
The following databases were searched: MEDLINE (Ovid platform 1946 to 24 January 2015); EMBASE (Ovid platform 1980 to 24 January 2015); CINAHL (Ebsco platform 1937 to 24 January 2015). Reference lists of the included RCTs and identified review articles were hand searched to find other potentially eligible studies. To ensure a large safety net, a sensitive search strategy was employed. We searched using a combination of MeSH headings and keywords (and their derivatives): mineralocorticoid receptor antagonists, aldosterone antagonist, spironolactone, epleronone, canrenone, heart failure, ventricular dysfunction (see also Appendix 1 in the supplementary data, available at Age and Ageing online). No language restrictions were applied. We searched for grey literature using Google and Google Scholar and also specifically searched for the drugs of interest on the websites of the US Food and Drug Administration and other European and international health regulatory authorities. We searched clinical trials registers (https://clinicaltrials.gov, www.clinicaltrialsregis ter.eu) for ongoing and unpublished trials.
The search of electronic databases was conducted by two independent reviewers who identified potentially relevant articles based on title or title and abstract. Full-text articles were then retrieved for further assessment to determine whether they met inclusion criteria. Discrepancies were resolved by consensus.
Quality assessment and data extraction
Relevant data were extracted and entered into a data collection form. Where available, outcomes data were extracted specifically for 'younger elderly' (65-74 years) and 'older elderly' (≥75 years) patients, as well as for patients with HEFREF and HEFPEF. Studies were assessed for quality using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system [16] , with scoring performed by two independent authors and differences resolved by consensus.
This systematic review was registered with PROSPERO, the international prospective register of systematic reviews (registration number CRD42013004478).
Data synthesis and analysis
Relative risk ratios were pooled where more than three estimates were available. Most studies reported hazards ratios. Some studies only provided proportional data, and in these cases, we calculated relative risk estimates derived from two by two contingency tables. We assumed that the 'true effect' estimate would be the same across all studies and initially derived overall pooled estimates using a fixed-effects model. In those meta-estimates where there was a high degree of heterogeneity (I 2 > 30%), we also provided estimates derived from a random effects model. Treatment effects and derived meta-estimates are expressed as risk ratios ± 95% confidence intervals (95% CI). Continuous variables, unless otherwise stated, were expressed as mean ± SD. Metaanalysis was performed using RevMan 5.3 software (The Cochrane Collaboration, Oxford, UK).
Results
One thousand eight hundred and sixty-four articles were identified by the initial search strategy and, of these, eight articles [10] [11] [12] [13] [14] [17] [18] [19] describing seven RCTs were included in the final review (Figure 1) . A subgroup study of the EMPHASIS-HF high risk [17] reported a prespecified analysis of efficacy and safety outcomes in trial patients ≥75 years. The original trial publication [12] included a subgroup analysis for the primary outcome in patients ≥65 years and was therefore also included. Study characteristics and quality are shown in Table 1 . Quality was generally moderate or high, and with one exception [18] the studies were double-blinded and placebo-controlled with sample size based on appropriate power calculations. Overall dropout rates were <20% in all Mineralocorticoid receptor antagonists in elderly patients with heart failure but one [10] of the studies while the differential dropout rate between the two treatment arms was <10% in all. One trial included a prespecified subgroup study in patients ≥75 years [17] , but otherwise, the studies containing subgroup analysis of older patients offered limited characterisation and outcome data specific to our population of interest; consequently, for the purposes of this review, their quality was graded as moderate. A comprehensive search of grey literature and regulatory health websites uncovered additional relevant data for three of the included RCTs (see Appendix 2 in the supplementary data, available at Age and Ageing online).
Efficacy outcomes HF with reduced ejection fraction
Three trials in patients with HEFREF reported relevant mortality and hospitalisation outcomes (Table 1, Figure 2 ). All reported an overall benefit from MRA therapy with respect to the individual trial's primary end point with no significant treatment interaction for age ( Table 1) . As shown in Figure 2 , the magnitude of treatment effect for these end points in older patients was broadly similar to that in younger patients. The major exception to this was in patients ≥75 years with post-MI HEFREF; in these patients, there was no apparent benefit from eplerenone treatment for either of the two co-primary end points; however, age ≥75 years was not examined as a treatment interaction term. Additionally, in patients ≥75 years with stable NYHA Class II HEFREF, the effect of eplerenone on the trial's primary composite end point was driven entirely by a reduction in hospitalisation for HF with no difference in CV mortality between the two treatment arms.
Even if not reported as a primary end point, we found data on all-cause mortality data in patients ≥75 and <75 years for all three HEFREF trials ( Figure 3 ). In patients <75 years, there was a substantial and highly significant reduction in mortality that was consistent across studies (odds ratio (OR) 0.74; 95% CI 0.66-0.83; P < 0.00001; I 2 = 5%). In contrast, in patients ≥75 years, we observed marked heterogeneity between studies (I 2 = 79%; P = 0.009). On a random effects model, there was no significant reduction in mortality in this elderly population with MRA therapy (OR 0.8; 95% CI 0.52-1.25; P = 0.33).
Specific hospitalisation data for elderly patients was obtained for only one of the HEFREF studies [17] .
Although not a prespecified analysis, eplerenone significantly reduced hospitalisation for HF ( Figure 2 ) and for cardiovascular causes (HR 0.62; CI 0.47-0.82) in patients ≥75 years with chronic stable HEFREF and NYHA Class II symptoms.
We found no data on the effects of MRA treatment on quality of life and/or functional capacity outcomes in older patients with HEFREF.
HF with preserved ejection fraction
In the single trial of patients with HEFPEF that reported mortality and hospitalisation outcomes, MRA therapy did not significantly reduce the incidence of the individual trial's primary composite outcome (Table 1, Figure 2 ). Hazard ratios for older patients were similar to those of the overall trial population, and there was no significant treatment interaction for age.
Three RCTs, all in patients with HEFPEF, reported limited quality of life and/or functional capacity outcomes J. Deepa et al. ( Table 1 ) in older patients. No significant treatment effects were observed for any of these outcomes.
Safety outcomes
Our specified safety end points were obtained from three studies (see Appendix 3 in the supplementary data, available at Age and Ageing online). In two large trials, the incidence of hyperkalaemia (K + ≥5.5 mmol/L) in patients ≥75 years was increased by MRA treatment. However, further data from one of these trials and a small trial of patients with mean age 71 years suggested a low overall incidence of severe hyperkalaemia (K + ≥6.0 mmol/L) or hospitalisation for hyperkalaemia with no significant difference in the frequency of these events between the two treatment arms. In one large trial, neither decline in estimated glomerular filtration rate from baseline nor incidence of hospitalisation for worsening renal function was increased by MRA treatment.
Discussion
This systematic review of MRA treatment in older patients with HF included seven RCTs with a total of 8,638 patients aged ≥65 years and >3,300 aged ≥75 years. Across the spectrum of HEFREF, we found no overall mortality benefit from MRA therapy in patients ≥75 years; however, MRAs did improve clinical outcomes (mortality and/or hospitalisations) in older patients with chronic stable HEFREF and in younger elderly patients with post-MI LVSD. There was no evidence of benefit from MRA treatment in elderly patients with HEFPEF.
An age threshold of 65 years is frequently used to define elderly patients in both clinical and research settings. This cutoff may no longer be appropriate in conditions such as HF where the majority of patients are >65 years. In contemporary population-based studies, the mean age of patients with HF is now 80 years [20] ; by comparison, the mean age of participants among large RCTs included in this review ranged from 64 to 68 years and patients ≥75 years contributed less than one-third of the combined trial population. Moreover, while other established therapies for HF including angiotensin converting enzyme (ACE) inhibitors and beta-blockers appear to be beneficial in 'younger' elderly patients, there is some evidence to suggest that they are less effective in patients ≥75 years [21, 22] . We therefore sought relevant outcomes data for patients ≥75 years as well as for all patients ≥65 years.
Across three large RCTs of MRAs in distinctive HEFREF populations, we observed a consistent mortality Figure 2 . Absolute events and risk/hazard ratios for relevant mortality and hospitalisation end points. *Unless otherwise stated, data represent relative risk ratios derived from 2 × 2 contingency tables.^Hazard ratios. CV, cardiovascular. reduction in patients <75 years. In the two trials for which data were available, treatment response in patients aged 65-74 years closely mirrored that of younger patients. In contrast, the effect of MRAs on mortality in older elderly patients displayed marked heterogeneity. In chronic stable HEFREF, MRA treatment caused a striking reduction in all-cause death in patients ≥75 years with NYHA Class III-IV symptoms. We were unable to ascertain the mode of death among specific age cohorts; however, within the overall trial population, MRAs reduced both sudden death and death from progressive HF. In a subsequent trial in NYHA Class II patients, MRA therapy had a neutral effect on mortality among patients ≥75 years but reduced hospitalisations for HF by over 40% This suggests that MRA treatment may serve to retard progression of HF in older patients with possible mechanisms including prevention of myocardial fibrosis and reduced sodium retention [23] . In contrast to chronic stable HEFREF, neither all-cause mortality nor the composite of CV mortality or CV hospitalisation was reduced by MRA treatment in patients ≥75 years with early post-MI LVSD.
The above data suggest that the response to MRAs among the older elderly with HEFREF may depend upon the particular patient subtype. However, we were unable to explore several other potential sources for the observed variation in treatment effect. The three trials included in our meta-analysis spanned a recruitment period of 15 years, during which time background drug and device therapy underwent considerable change. Indeed, the background use of beta-blockers in the trials varied from 10% [10] to 87% [12] . The trials also employed two different investigational drugs (spironolactone and eplerenone) and had populations that differed with respect to comorbidities, LV ejection fraction and aetiology of LVSD. Compounding this, the baseline characteristics of elderly patients were available for only one of the studies. We therefore call for an individual patient data meta-analysis of these RCTs to further explore the sources of heterogeneity in treatment response to MRAs among the older elderly, as well as to clarify the effects in elderly patients <75 years and to evaluate other major outcomes of interest in elderly patients. Beyond this, subgroup analysis from the forthcoming trial of early post-MI spironolactone treatment (Aldosterone Blockade Early After Acute Myocardial Infarction, ALBATROSS, NCT01059136) may provide further insights into the utility of MRAs in older elderly patients with post-MI LVSD.
No treatments have yet been convincingly shown to improve outcomes in HEFPEF, the predominant form of HF among older patients [6, 24] . One large RCT with subgroup analysis in elderly patients reported the effects of MRA therapy on major clinical outcomes in HEFPEF [14] . While MRA treatment did not reduce the primary composite outcome within the overall study population, interpretation of the results has been complicated by marked geographical variation with respect to both patient profile and treatment effect [25] . No such variation in response to treatment was observed by patient age and outcomes in both the older elderly and younger elderly patients appeared similar to those of non-elderly patients. We found limited data regarding the effects of MRAs on other efficacy outcomes in elderly HEFPEF patients; however, two trials showed no apparent benefit on exercise capacity. Further work is now required to determine whether distinct subpopulations of elderly patients with HEFPEF may derive benefit from MRA therapy. Future studies should ideally include more robust assessments of symptoms, functional capacity and quality of life in addition to mortality and hospitalisation outcomes.
The available safety data in this review confirms an increased risk of hyperkalaemia with MRA treatment in patients ≥75 years. However, in the single large RCT for which comprehensive safety data were available, the rates of severe hyperkalaemia, hyperkalaemia requiring hospitalisation or hospitalisation for worsening renal function were all very low and did not differ from elderly patients in the placebo arm. Registry studies comprising real world patients have reported considerably higher rates of serious safety outcomes with MRA treatment in older people, particularly hyperkalaemia [26, 27] . This may in part be explained by more indiscriminate use of MRAs in everyday clinical practice among patients at risk of complications. Indeed >30% of Medicare beneficiaries prescribed spironolactone shortly after the publication of the Randomised Aldactone Evaluation Study (RALES) would have been ineligible for inclusion in RALES on account of baseline renal function or serum potassium [27] . While such real world studies reinforce the need for caution when prescribing MRAs to older patients, the limited data in this review suggest that the risks of serious complications can be mitigated through careful patient selection, monitoring and dose adjustment. Future studies with large elderly representation should consider additional safety end points relevant to older people such as the incidence of falls, fractures or cognitive deterioration.
Study limitations
The number of studies identified was relatively small, and we are unable to exclude the possibility of publication bias. Furthermore, the original trial publications relating to these studies contained very limited data specific to elderly patients and we had no access to the primary trial data. Much of the data included in the review were, therefore, previously unpublished and obtained from formal assessments by regulatory health authorities available on publically accessible websites. While this may also be viewed as a strength of our search process, the results obtained were unavoidably sparse and, in several areas, incomplete. This could be addressed by future individual patient data metaanalysis of the major MRA RCTs in HEFREF as well as further dedicated study of MRAs in specific elderly HF cohorts.
We found little evidence for the effects of MRAs on efficacy outcomes other than mortality, particularly in the setting of HEFREF. The absence of robust evidence for outcomes such as quality of life and symptom status is disappointing as their importance, relative to mortality, is likely to increase with advancing age. We urge greater inclusion of these end points in subsequent trials, particularly those with major elderly representation. All of the included studies used either spironolactone or eplerenone. Further work is required to evaluate the effects of canrenone and the novel, non-steroidal MRA, finrenone, in older HF patients.
The literature under-represents the main population of older people with HF, mostly in their 80s and 90s. The presence of certain comorbid conditions such as diabetes, chronic kidney disease and chronic obstructive pulmonary were frequently reported; however, other comorbidities such as cognitive impairment were not routinely recorded and none of the studies undertook a formal assessment of frailty.
Conclusions
The effect of MRAs on all-cause mortality in older patients is uncertain, but they improve several major clinical outcomes in older patients with chronic HEFREF and in those aged <75 years with post-MI LVSD. In contrast, there is no evidence to support MRA treatment in older patients with HEFPEF. While MRAs increase the risk of mild hyperkalaemia, limited data do not suggest major safety concerns in carefully selected and monitored elderly patients. Further study, with efficacy and safety outcomes relevant to older people, is required, particularly the older elderly.
Key points
• Elderly patients under-represented in HF clinical trials • First systematic review of MRAs in older patients with HF.
• No benefit from MRAs in elderly patients with HF and normal LV ejection fraction.
• Benefits of MRAs broadly maintained in older patients with chronic stable HF and reduced LV ejection fraction.
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